ubx-10q_20200630.htm
false 2020 Q2 0001463361 --12-31 Accelerated Filer true P8Y9M18D 0001463361 2020-01-01 2020-06-30 xbrli:shares 0001463361 2020-07-27 iso4217:USD 0001463361 2020-06-30 0001463361 2019-12-31 iso4217:USD xbrli:shares 0001463361 2020-04-01 2020-06-30 0001463361 2019-04-01 2019-06-30 0001463361 2019-01-01 2019-06-30 0001463361 us-gaap:CommonStockMember 2019-12-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2019-12-31 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2019-12-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001463361 us-gaap:RetainedEarningsMember 2019-12-31 0001463361 us-gaap:CommonStockMember ubx:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0001463361 us-gaap:AdditionalPaidInCapitalMember ubx:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0001463361 ubx:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0001463361 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001463361 2020-01-01 2020-03-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001463361 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001463361 us-gaap:CommonStockMember 2020-03-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2020-03-31 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2020-03-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001463361 us-gaap:RetainedEarningsMember 2020-03-31 0001463361 2020-03-31 0001463361 us-gaap:CommonStockMember ubx:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0001463361 us-gaap:AdditionalPaidInCapitalMember ubx:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0001463361 ubx:AtTheMarketEquityOfferingProgramMember 2020-04-01 2020-06-30 0001463361 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001463361 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2020-04-01 2020-06-30 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001463361 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001463361 us-gaap:CommonStockMember 2020-06-30 0001463361 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2020-06-30 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2020-06-30 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001463361 us-gaap:RetainedEarningsMember 2020-06-30 0001463361 us-gaap:CommonStockMember 2018-12-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2018-12-31 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2018-12-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001463361 us-gaap:RetainedEarningsMember 2018-12-31 0001463361 2018-12-31 0001463361 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001463361 2019-01-01 2019-03-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001463361 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001463361 us-gaap:CommonStockMember 2019-03-31 0001463361 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2019-03-31 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2019-03-31 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001463361 us-gaap:RetainedEarningsMember 2019-03-31 0001463361 2019-03-31 0001463361 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001463361 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001463361 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001463361 us-gaap:CommonStockMember 2019-06-30 0001463361 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001463361 ubx:RelatedPartyPromissoryNotesForPurchaseOfCommonStockMember 2019-06-30 0001463361 ubx:EmployeePromissoryNotesForPurchaseOfCommonStockMember 2019-06-30 0001463361 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001463361 us-gaap:RetainedEarningsMember 2019-06-30 0001463361 2019-06-30 ubx:Segment 0001463361 srt:MaximumMember 2020-01-01 2020-06-30 0001463361 us-gaap:AccountingStandardsUpdate201602Member 2020-01-01 0001463361 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001463361 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001463361 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001463361 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001463361 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001463361 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001463361 ubx:ForeignEquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 ubx:ForeignEquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001463361 ubx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001463361 ubx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember ubx:ForeignEquitySecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ubx:ForeignEquitySecuritiesMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember ubx:ContingentConsiderationLiabilityMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ubx:ContingentConsiderationLiabilityMember 2019-12-31 0001463361 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001463361 ubx:CommercialAgreementMember ubx:ClinicalStageBiopharmaceuticalCompanyMember srt:MaximumMember 2020-01-01 2020-06-30 xbrli:pure 0001463361 srt:MinimumMember 2020-06-30 0001463361 srt:MaximumMember 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:ClinicalStageBiopharmaceuticalCompanyMember srt:MaximumMember ubx:ContingentConsiderationMember 2020-06-30 0001463361 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-06-30 0001463361 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001463361 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-06-30 0001463361 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001463361 us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-06-30 0001463361 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-06-30 0001463361 ubx:CommercialAgreementMember ubx:ClinicalStageBiopharmaceuticalCompanyMember 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:ClinicalStageBiopharmaceuticalCompanyMember 2019-12-31 0001463361 ubx:LicenseAndCompoundLibraryAndOptionAgreementMember 2020-01-01 2020-06-30 0001463361 ubx:LicenseAndCompoundLibraryAndOptionAgreementMember 2019-01-01 2019-06-30 0001463361 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2020-06-30 0001463361 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2020-06-30 0001463361 us-gaap:CashEquivalentsMember 2020-06-30 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:CommercialPaperMember 2020-06-30 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0001463361 ubx:ShortTermMarketableSecuritiesMember ubx:USTreasuriesMember 2020-06-30 0001463361 ubx:ShortTermMarketableSecuritiesMember 2020-06-30 0001463361 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001463361 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2019-12-31 0001463361 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001463361 us-gaap:CashEquivalentsMember 2019-12-31 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:CommercialPaperMember 2019-12-31 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001463361 ubx:ShortTermMarketableSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001463361 ubx:ShortTermMarketableSecuritiesMember ubx:USTreasuriesMember 2019-12-31 0001463361 ubx:ShortTermMarketableSecuritiesMember 2019-12-31 0001463361 ubx:LongTermMarketableSecuritiesMember ubx:USTreasuriesMember 2019-12-31 0001463361 ubx:LongTermMarketableSecuritiesMember 2019-12-31 0001463361 ubx:ClinicalStageBiopharmaceuticalCompanyMember ubx:CommercialAgreementMember ubx:InitialLicenseAgreementMember 2020-01-01 2020-06-30 0001463361 ubx:ClinicalStageBiopharmaceuticalCompanyMember ubx:CommercialAgreementMember ubx:SecondLicenseAgreementMember 2020-01-01 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:ClinicalStageBiopharmaceuticalCompanyMember 2020-01-01 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:AcademicInstitutionMember 2020-01-01 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:AcademicInstitutionMember 2020-06-30 0001463361 ubx:ClinicalStageBiopharmaceuticalCompanyMember ubx:CommercialAgreementMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-01 0001463361 ubx:LicensedProductsMember 2020-01-01 2020-06-30 0001463361 ubx:CommercialAgreementMember ubx:AffiliateOfClinicalStageBiopharmaceuticalCompanyMember 2016-04-01 2016-04-30 0001463361 ubx:CommercialAgreementMember ubx:AffiliateOfClinicalStageBiopharmaceuticalCompanyMember 2018-05-31 iso4217:HKD xbrli:shares 0001463361 us-gaap:IPOMember ubx:LicenseAndCompoundLibraryAndOptionAgreementMember us-gaap:CommonStockMember 2019-10-31 0001463361 ubx:ClinicalStageBiopharmaceuticalCompanyMember srt:MaximumMember ubx:CommercialAgreementMember 2020-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember ubx:TheRegentsOfUniversityOfCaliforniaOnBehalfItsSanFranciscoCampusMember us-gaap:CommonStockMember 2019-06-01 2019-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember ubx:TheRegentsOfUniversityOfCaliforniaOnBehalfItsSanFranciscoCampusMember us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember ubx:TheRegentsOfUniversityOfCaliforniaOnBehalfItsSanFranciscoCampusMember 2019-06-01 2019-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember ubx:TheRegentsOfUniversityOfCaliforniaOnBehalfItsSanFranciscoCampusMember 2020-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember 2020-06-30 0001463361 ubx:LicensingAgreementsWithResearchInstitutionsMember 2019-12-31 0001463361 ubx:SouthSanFranciscoCaliforniaMember 2020-01-01 2020-06-30 0001463361 ubx:SouthSanFranciscoCaliforniaMember 2020-06-30 0001463361 ubx:SouthSanFranciscoCaliforniaMember ubx:DeferredRentAndLeaseholdImprovementsMember 2019-12-31 0001463361 ubx:BrisbaneCaliforniaMember 2020-01-01 2020-06-30 0001463361 ubx:BrisbaneCaliforniaMember 2020-06-30 0001463361 us-gaap:AccountingStandardsUpdate201602Member ubx:Topic842AdjustmentsMember 2020-01-01 0001463361 us-gaap:AccountingStandardsUpdate201602Member ubx:AfterTopic842AdjustmentsMember 2020-01-01 0001463361 us-gaap:AccountingStandardsUpdate201602Member 2019-12-31 0001463361 ubx:RightOfUseAssetsMember ubx:SouthSanFranciscoCaliforniaMember 2020-01-01 2020-06-30 0001463361 us-gaap:LeaseholdImprovementsMember ubx:SouthSanFranciscoCaliforniaMember 2020-01-01 2020-06-30 0001463361 2019-06-01 2019-06-30 0001463361 ubx:AtTheMarketEquityOfferingProgramMember us-gaap:CommonStockMember 2019-06-01 2019-06-30 0001463361 ubx:SalesAgreementMember ubx:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember ubx:AtTheMarketEquityOfferingProgramMember 2019-06-03 2019-06-03 0001463361 ubx:SalesAgreementMember ubx:CowenAndCompanyLimitedLiabilityCompanyMember ubx:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-06-30 0001463361 ubx:RestrictedStockUnitsAndPerformanceStockUnitsMember 2019-12-31 0001463361 ubx:RestrictedStockUnitsAndPerformanceStockUnitsMember 2020-01-01 2020-06-30 0001463361 ubx:RestrictedStockUnitsAndPerformanceStockUnitsMember 2020-06-30 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:EmployeeStockOptionMember 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:PerformanceSharesMember 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:CommonStockMember 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:CommonStockMember 2020-03-01 2020-03-31 0001463361 ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001463361 2020-03-01 2020-03-31 0001463361 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-31 0001463361 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-01 2020-03-31 0001463361 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-01 2020-03-31 0001463361 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-31 0001463361 us-gaap:PerformanceSharesMember ubx:TwoThousandTwentyEmploymentInducementIncentivePlanMember 2020-03-01 2020-03-31 0001463361 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001463361 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001463361 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001463361 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001463361 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001463361 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001463361 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001463361 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001463361 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001463361 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001463361 ubx:EarlyExercisedCommonStockSubjectToFutureVestingMember 2020-01-01 2020-06-30 0001463361 ubx:EarlyExercisedCommonStockSubjectToFutureVestingMember 2019-01-01 2019-06-30 0001463361 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001463361 ubx:SharesSubjectToEmployeeStockPurchasePlanMember 2020-01-01 2020-06-30 0001463361 ubx:SharesSubjectToEmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001463361 us-gaap:LicenseAgreementTermsMember us-gaap:SubsequentEventMember ubx:AscentageInternationalMember 2020-07-30 2020-07-30 0001463361 srt:MaximumMember ubx:July2020SalesAgreementMember ubx:CowenAndCompanyLimitedLiabilityCompanyMember ubx:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2020-07-31 2020-07-31 0001463361 ubx:July2020SalesAgreementMember ubx:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _________

Commission File Number: 001-38470

 

Unity Biotechnology, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

26-4726035

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

285 East Grand Ave.

South San Francisco, CA

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 416-1192

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

UBX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No 

As of July 27, 2020, the registrant had 52,040,018 shares of common stock outstanding.

 


UNITY BIOTECHNOLOGY, INC.

QUARTERLY REPORT ON FORM 10-Q

Table of Contents

 

PART I. FINANCIAL INFORMATION

 

Item 1

Condensed Financial Statements

2

 

Condensed Balance Sheets as of June 30, 2020 (unaudited) and December 31, 2019

2

 

Condensed Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2020 and 2019 (unaudited)

3

 

Condensed Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2020 and 2019 (unaudited)

4

 

Condensed Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019 (unaudited)

6

 

Notes to Condensed Financial Statements (unaudited)

7

Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3

Quantitative and Qualitative Disclosures About Market Risk

36

Item 4

Controls and Procedures

36

 

 

 

PART II. OTHER INFORMATION

 

 

 

Item 1

Legal Proceedings

37

Item 1A

Risk Factors

37

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

85

Item 3

Default Upon Senior Securities

85

Item 4

Mine Safety Disclosures

85

Item 5

Other Information

85

Item 6

Exhibits

87

Signatures

89

 

 

1


PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

 

Unity Biotechnology, Inc.

Condensed Balance Sheets

(In thousands, except for share amounts and par value)

 

 

 

June 30,

2020

 

 

December 31,

2019

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

39,592

 

 

$

37,473

 

Short-term marketable securities

 

 

72,176

 

 

 

84,508

 

Strategic investment

 

 

7,768

 

 

 

5,507

 

Prepaid expenses and other current assets

 

 

4,001

 

 

 

1,999

 

Total current assets

 

 

123,537

 

 

 

129,487

 

Property and equipment, net

 

 

14,226

 

 

 

16,636

 

Operating lease right of use asset

 

 

24,891

 

 

 

 

Long-term marketable securities

 

 

 

 

 

3,025

 

Restricted cash

 

 

1,446

 

 

 

1,446

 

Other long-term assets

 

 

598

 

 

 

627

 

Total assets

 

$

164,698

 

 

$

151,221

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,952

 

 

$

5,185

 

Accrued compensation

 

 

3,651

 

 

 

5,905

 

Accrued and other current liabilities

 

 

6,250

 

 

 

4,995

 

Contingent consideration liability

 

 

1,816

 

 

 

1,131

 

Total current liabilities

 

 

15,669

 

 

 

17,216

 

Operating lease liability, net of current portion

 

 

36,770

 

 

 

 

Deferred rent, net of current portion

 

 

 

 

 

13,298

 

Total liabilities

 

 

52,439

 

 

 

30,514

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Convertible preferred stock, $0.0001 par value; 10,000,000 shares

   authorized; no shares issued and outstanding

 

 

 

 

 

 

Common stock, $0.0001 par value; 300,000,000 shares

   authorized as of June 30, 2020 and December 31, 2019;

   51,729,511 and 47,227,065 shares issued and outstanding

   as of June 30, 2020 and December 31, 2019, respectively

 

 

5

 

 

 

5

 

Additional paid-in capital

 

 

404,754

 

 

 

366,695

 

Related party promissory notes for purchase of common stock

 

 

(210

)

 

 

(210

)

Employee promissory notes for purchase of common stock

 

 

(362

)

 

 

(418

)

Accumulated other comprehensive income

 

 

232

 

 

 

90

 

Accumulated deficit

 

 

(292,160

)

 

 

(245,455

)

Total stockholders’ equity

 

 

112,259

 

 

 

120,707

 

Total liabilities and stockholders’ equity

 

$

164,698

 

 

$

151,221

 

 

See accompanying notes to the condensed financial statements.

2


Unity Biotechnology, Inc.

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

16,123

 

 

$

18,468

 

 

$

35,388

 

 

$

34,973

 

General and administrative

 

 

6,320

 

 

 

4,970

 

 

 

12,273

 

 

 

9,447

 

Change in fair value of contingent consideration

 

 

906

 

 

 

1,032

 

 

 

685

 

 

 

(213

)

Impairment of long-lived assets

 

 

 

 

 

 

 

 

2,159

 

 

 

 

Total operating expenses

 

 

23,349

 

 

 

24,470

 

 

 

50,505

 

 

 

44,207

 

Loss from operations

 

 

(23,349

)

 

 

(24,470

)

 

 

(50,505

)

 

 

(44,207

)

Interest income

 

 

340

 

 

 

900

 

 

 

867

 

 

 

1,906

 

Other income (expense), net

 

 

4,342

 

 

 

(103

)

 

 

2,933

 

 

 

(139

)

Net loss

 

 

(18,667

)

 

 

(23,673

)

 

 

(46,705

)

 

 

(42,440

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on marketable debt

  securities

 

 

(141

)

 

 

94

 

 

 

142

 

 

 

208

 

Comprehensive loss

 

$

(18,808

)

 

$

(23,579

)

 

$

(46,563

)

 

$

(42,232

)

Net loss per share, basic and diluted

 

$

(0.38

)

 

$

(0.56

)

 

$

(0.96

)

 

$

(1.00

)

Weighted-average number of shares used in

  computing net loss per share, basic and diluted

 

 

49,659,153

 

 

 

42,442,886

 

 

 

48,606,768

 

 

 

42,311,040

 

 

See accompanying notes to the condensed financial statements.


 

3


Unity Biotechnology, Inc.

Condensed Statements of Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

For the Six Months Ended June 30, 2020

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Related Party

Promissory Notes

for Purchase of

 

 

Employee Promissory Notes for Purchase of

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Common Stock

 

 

Common Stock

 

 

Gain (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2019

 

 

47,227,065

 

 

$

5

 

 

$

366,695

 

 

$

(210

)

 

$

(418

)

 

$

90

 

 

$

(245,455

)

 

$

120,707

 

Issuance of common stock, net of issuance costs,

   under at-the-market ("ATM") equity offering program

 

 

1,513,840

 

 

 

 

 

 

8,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8,763

 

Issuance of common stock upon exercise of stock options

 

 

73,049

 

 

 

 

 

 

249

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

249

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

40

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

40

 

Stock-based compensation

 

 

 

 

 

 

 

 

3,225

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,225

 

Common stock issued for services

 

 

43,550

 

 

 

 

 

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

100

 

Change in unrealized gain on available-for-sale

   marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

283

 

 

 

 

 

 

283

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(28,038

)

 

 

(28,038

)

Balances at March 31, 2020

 

 

48,857,504

 

 

$

5

 

 

$

379,072

 

 

$

(210

)

 

$

(418

)

 

$

373

 

 

$

(273,493

)

 

$

105,329

 

Issuance of common stock, net of issuance costs,

   under ATM equity offering program

 

 

2,594,030

 

 

 

 

 

 

20,731

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20,731

 

Issuance of common stock upon exercise of stock options

 

 

105,142

 

 

 

 

 

 

355

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

355

 

Issuance of common stock from restricted stock units

 

 

103,020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

132

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

132

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,079

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,079

 

Issuance of common stock under employee stock

  purchase plan ("2018 ESPP")

 

 

69,815

 

 

 

 

 

 

385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

385

 

Repayment of promissory note from employee from

  purchase of common stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

56

 

 

 

 

 

 

 

 

 

56

 

Change in unrealized loss on available-for-sale

   marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(141

)

 

 

 

 

 

(141

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,667

)

 

 

(18,667

)

Balances at June 30, 2020

 

 

51,729,511

 

 

$

5

 

 

$

404,754

 

 

$

(210

)

 

$

(362

)

 

$

232

 

 

$

(292,160

)

 

$

112,259

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4


 

For the Six Months Ended June 30, 2019

 

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Related Party

Promissory Notes

for Purchase of

 

 

Employee Promissory Notes for Purchase of

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Common Stock

 

 

Common Stock

 

 

Gain (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2018

 

 

42,414,294

 

 

$

4

 

 

$

324,663

 

 

$

(201

)

 

$

(400

)

 

$

(95

)

 

$

(163,278

)

 

$

160,693

 

Issuance of common stock upon exercise of stock options

 

 

340,731

 

 

 

 

 

 

300

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

300

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

207

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

207

 

Stock-based compensation

 

 

 

 

 

 

 

 

1,997

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,997

 

Common stock issued to third parties

 

 

133,334

 

 

 

 

 

 

2,059

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,059

 

Change in unrealized gain on available-for-sale

   marketable debt securities, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

114

 

 

 

 

 

 

114

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,767

)

 

 

(18,767

)

Balances at March 31, 2019

 

 

42,888,359

 

 

$

4

 

 

$

329,226

 

 

$

(201

)

 

$

(400

)

 

$

19

 

 

$

(182,045

)

 

$

146,603

 

Issuance of common stock upon exercise of stock options

 

 

147,832

 

 

 

 

 

 

494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

494

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

218

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

218

 

Stock-based compensation

 

 

 

 

 

 

 

 

1,944

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,944

 

Repurchased shares

 

 

(3,793

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under 2018 ESPP

 

 

51,201

 

 

 

 

 

 

405

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

405

 

Common stock issued to third party for a license

 

 

120,000

 

 

 

 

 

 

965

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

965

 

Change in unrealized gain on available-for-sale

  marketable debt securities, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

94

 

 

 

 

 

 

94

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(23,673

)

 

 

(23,673

)

Balances at June 30, 2019

 

 

43,203,599

 

 

$

4

 

 

$

333,252

 

 

$

(201

)

 

$

(400

)

 

$

113

 

 

$

(205,718

)

 

$

127,050

 

 

See accompanying notes to the condensed financial statements.

 

5


Unity Biotechnology, Inc.

Condensed Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019